Sex chromosomes/hormones and the tumor microenvironment of non-reproductive cancers Chun-Miao Zhang, Zhong-Bo Ge, Hai-Hong Zhou, Meng-Xiao Wei, Xin-Yuan Ding, Zhe-Zheng Lin, Ming-Yu Wang, Cai-Juan Bai Frontiers in Immunology.2025;[Epub] CrossRef
Rising burden of steatotic liver disease in women of childbearing age and projections till 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2025; : 101646. CrossRef
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol 2025;31(3):1058-1070. Published online April 11, 2025
Background/Aims Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021.
Methods Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US.
Results In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the US. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (annual percent change [APC] 2.21%, 95% confidence interval [CI] 1.70–2.73%) and other pharyngeal cancer (APC 1.35%, 95% CI 1.08–1.62%).
Conclusions The burden of ALD is substantial and continues to rise in the US, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcoholattributable extrahepatic malignancies.
Citations
Citations to this article as recorded by
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2026; 8(1): 101646. CrossRef
MetALD: new insights and unraveling therapeutic potential Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul Liver International.2025;[Epub] CrossRef
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications” Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Alcohol use and cirrhosis in women: An underestimated risk P. Huerta, J.P. Arab, L.A. Díaz Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef
Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV). Alternative surveillance tools such as blood-based biomarker panels and abbreviated magnetic resonance imaging (MRI) are being investigated. Multiphasic computed tomography or MRI is the standard for HCC diagnosis, but histological confirmation should be considered, especially when inconclusive findings are seen on cross-sectional imaging. Staging and treatment decisions are complex and should be made in multidisciplinary settings, incorporating multiple factors including tumor burden, degree of liver dysfunction, patient performance status, available expertise, and patient preferences. Early-stage HCC is best treated with curative options such as resection, ablation, or transplantation. For intermediate-stage disease, locoregional therapies are primarily recommended although systemic therapies may be preferred for patients with large intrahepatic tumor burden. In advanced-stage disease, immune checkpoint inhibitor-based therapy is the preferred treatment regimen. In this review article, we discuss the recent global epidemiology, risk factors, and HCC care continuum encompassing surveillance, diagnosis, staging, and treatments.
Citations
Citations to this article as recorded by
Gender, Age, Alpha-fetoprotein, and Des-gamma-carboxyprothrombin Score as a Novel Approach to Early Detection of Hepatocellular Carcinoma: A Narrative Review Ludovico Abenavoli, Giuseppe G.M. Scarlata, Maria L. Gambardella, Ivo Lopez, Giuseppe Sena, Domenico Laganà, Francesco Luzza, Giuseppe Currò Journal of Clinical and Experimental Hepatology.2026; 16(1): 103203. CrossRef
Split biosensor based on nano-enzymatic ferrocene-tyramine deposition reaction for detection of SMP30 antibody Yanping Xing, Xixiang Xie, Jiangtao Liu, Tao Zhao, Xiyu Liu, Pan Wu, Faquan Lin, Yong Huang Analytica Chimica Acta.2026; 1382: 344834. CrossRef
Ferroptosis modulation by METTL14 in cancers: From molecular insights to therapeutic strategies Boran Huang, Chenglin Zhu, Xinyu Zhang, Qi Zhang, Honggang Wang Cellular Signalling.2026; 138: 112212. CrossRef
Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis Anqi Wang, Sitong Yan, Weijia Jiang, Xiang Chen, Yuhan Huang, Xiangyu Zu, Xiao Du, Lulu Fan, Jiatao Liu, Guoping Sun BMC Cancer.2025;[Epub] CrossRef
Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer Xin Wei, Weihua Cao, Shiyu Wang, Yaqin Zhang, Zixuan Gao, Shuojie Wang, Linmei Yao, Ziyu Zhang, Xinxin Li, Wen Deng, Yao Xie, Minghui Li International Journal of Nanomedicine.2025; Volume 20: 2623. CrossRef
Rising Incidence of Early-Onset Liver Cancer and Intrahepatic Bile Duct Cancer: Analysis of the National Childhood Cancer Registry Database Pojsakorn Danpanichkul, Yanfang Pang, Thanida Auttapracha, Omar Al Ta’ani, Thanathip Suenghataiphorn, Apichat Kaewdech, Mark D. Muthiah, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Cancers.2025; 17(7): 1133. CrossRef
Role of SMYD2 in gastrointestinal cancer progression (Review) Kun Xia, Yaoxiang Zhou, Youping Xie, Yinzhong Cai Oncology Letters.2025; 29(6): 1. CrossRef
Longitudinal study of factors associated with the anti-cancer efficacy and liver function in HCC patients treated with TACE in combination with percutaneous ablation Huhu Ren, Jian Chen, Zhiqun Wu, Chen Li Frontiers in Oncology.2025;[Epub] CrossRef
A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D. Muthiah, Won-Mook Choi Current Hepatology Reports.2025;[Epub] CrossRef
LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ Gegentuya Bao, Manjue Zhai, Yali Yan, Yuewu Wang, Alatangaole Damirin International Journal of Molecular Sciences.2025; 26(9): 4205. CrossRef
PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma Jitong Zhou, Meng Gao, Shikun Zhang, Wing‐Wa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma Advanced Science.2025;[Epub] CrossRef
Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis 舒惟 梁 Advances in Clinical Medicine.2025; 15(05): 2063. CrossRef
Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor Yufei Deng, Bangya Yang, Zelan Yang, Hanyu Xiao, Yan Zou, Cheng Zou, Song Yang, Xi Sun, Yiting Wang, Jin Bai, Liaoqiong Fang, Zhibiao Wang International Journal of Nanomedicine.2025; Volume 20: 6573. CrossRef
Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC Hee Sun Cho, Soon Kyu Lee, Ji Won Han, Jung Hyun Kwon, Soon Woo Nam, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi Frontiers in Immunology.2025;[Epub] CrossRef
Adding salt to foods and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases Shunming Zhang, Zhenyu Huo, Yan Borné, Emily Sonestedt, Lu Qi European Journal of Nutrition.2025;[Epub] CrossRef
Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications Chang-Lei Li, Zhi-Yuan Yao, Ao Sun, Jing-Yu Cao, Zu-Sen Wang Frontiers in Pharmacology.2025;[Epub] CrossRef
Molecular mechanisms underlying Fagopyrum dibotrys-derived nanovesicles induced ferroptosis in hepatocellular carcinoma: a dual-pathway analysis of lipid peroxidation and mitochondrial damage Ling Wu, Hongyao Chen, Jingting Zhang, Jincheng Tang, Zhibin Wang, Peisen Xue, Wenhui Gao, Renyi Yang, Puhua Zeng Frontiers in Pharmacology.2025;[Epub] CrossRef
An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations Xuebing Zhang, Liuxin Yang, Chengxiang Liu, Xingxing Yuan, Yali Zhang International Journal of General Medicine.2025; Volume 18: 3581. CrossRef
Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions Janthakan Wongsuwan, Teeravut Tubtawee, Sitang Nirattisaikul, Pojsakorn Danpanichkul, Wisit Cheungpasitporn, Sitthichok Chaichulee, Apichat Kaewdech BMJ Open Gastroenterology.2025; 12(1): e001832. CrossRef
Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults Fan Zhang, Yuan Xue, Wenjian Li BMC Geriatrics.2025;[Epub] CrossRef
Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma Junjie Gao, Meijun Zhang, Qun Chen, Kai Ye, Jing Wu, Tao Wang, Puhong Zhang, Gang Feng International Journal of Surgery.2025; 111(7): 4539. CrossRef
Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors Mohammad Saeid Rezaee-Zavareh, Soo Young Hwang, Naomy Kim, Hasmik Adetyan, Nguyen H. Tran, Ju Dong Yang Discover Oncology.2025;[Epub] CrossRef
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials Mohamed El-Kassas, Hend Shousha, Lewis R Roberts The Lancet Gastroenterology & Hepatology.2025; 10(11): 966. CrossRef
Response Assessment in Hepatocellular Carcinoma: A Primer for Radiologists Nayla Mroueh, Jinjin Cao, Shravya Srinivas Rao, Soumyadeep Ghosh, Ok Kyu Song, Sasiprang Kongboonvijit, Anuradha Shenoy-Bhangle, Avinash Kambadakone Journal of Computer Assisted Tomography.2025;[Epub] CrossRef
Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma Fen Liu, Xianying Li, Yiming Zhang, Shan Ge, Zhan Shi, Qingbin Liu, Shulong Jiang Journal of Experimental & Clinical Cancer Research.2025;[Epub] CrossRef
Hepatocellular carcinoma of non-viral etiology: From theory to real practice V. V. Petkau, N. E. Krasilnikova, E. N. Bessonova, A. A. Tarkhanov Meditsinskiy sovet = Medical Council.2025; (10): 66. CrossRef
The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC Jiaxin Huang, Jiaqi Tan, Nanfeng Meng, Junrong Wang, Peng Han, Hang Wang Expert Review of Anticancer Therapy.2025; 25(11): 1299. CrossRef
A Clinical-Imaging Nomogram for Predicting Early Recurrence in Patients with Solitary Hepatocellular Carcinoma After Postoperative Adjuvant TACE Jiachen Liu, Xiurong Ding, Yanyan Zhang, Hongjun Li Journal of Hepatocellular Carcinoma.2025; Volume 12: 1835. CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications” Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Augmenting conventional criteria: a CT-based deep learning radiomics nomogram for early recurrence risk stratification in hepatocellular carcinoma after liver transplantation Ziqian Wu, Danyang Liu, Siyu Ouyang, Jingyi Hu, Jie Ding, Qiu Guo, Jidong Gao, Jiawen Luo, Ke Ren Insights into Imaging.2025;[Epub] CrossRef
Exploration of the Mechanism of Action of Dendrobium officinale in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation Shuimeng Zhan, Xinyan Lu, Hongyan Guo, Yang Liu, Zhi Li, Wei Xu, Fang Xia, Huanjun Tang, Yi Tian, Jing Chen, Xuan Lin Journal of Hepatocellular Carcinoma.2025; Volume 12: 1973. CrossRef
Direct-acting Antivirals Therapy for Hepatocellular Carcinoma in Hepatitis C Patients Seul Ki Han, Soon Koo Baik, Moon Young Kim Journal of Digestive Cancer Research.2025; 13(2): 150. CrossRef
Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Diagnostic and Interventional Imaging.2025;[Epub] CrossRef
Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma Luca Filippi Seminars in Nuclear Medicine.2025; 55(6): 928. CrossRef
Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma Yuting Gao, Yi Gong, Xiaoyong Song, Yajun Xiong, Junlan Lu, Yanguang Yang, Yanli Gong, Zhimin Du, Shanshan Wang, Ruilong Jia, Peng Gong, Xinli Shi Phytomedicine.2025; 148: 157307. CrossRef
ANTIFIBROTIC STRATEGY IN THE TREATMENT OF CHRONIC LIVER DISEASES Mariana M. Seliuk, Anatolii M. Pechinka Ukrainian educational and scientific medical space.2025; (1): 28. CrossRef
The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT Huanyu Gong, Yong Cheng, Qiang Li, Yingjun He, Qijun Cai, Yongjin Tang, Yulong Liu, Lu Kuang, Yingxin Li, Jingjie Shang, Chengzhi Li, Kangshou Liu, Mingrong Cao, Lu Wang, Xueying Ling, Hao Xu European Journal of Nuclear Medicine and Molecular Imaging.2025;[Epub] CrossRef
Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization Sultan R. Alharbi Diagnostics.2025; 15(19): 2533. CrossRef
Binding and ubiquitination-mediated degradation of ACKR3 by the novel Scutellarein derivative TBS6b potently suppresses hepatocellular carcinoma Xing Jiang, Ying Liang, Guotao Tang, Haiyan Quan, Lijun Ruan, Mengli Zhang, Zhijun Song, Min Ou, Zhien Tan, Na Lu, Fangfang Wu, Xiaonan Yang Bioorganic Chemistry.2025; 166: 109073. CrossRef
Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Kyoung A Ko, Hyunwoo Oh, Myung Sub Kim, Hyun Pyo Hong, Yong Kyun Cho, Byung Ik Kim, Won Sohn Journal of Gastroenterology and Hepatology.2025; 40(11): 2758. CrossRef
Innovative Approaches to Hepatocellular Carcinoma: Diagnostic Breakthroughs, Biomarker Integration, and Artificial Intelligence Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Michalis V. Karamouzis Biomedicines.2025; 13(10): 2439. CrossRef
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo Clinical Cancer Research.2025; 31(20): 4323. CrossRef
Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma Fangmin Zhong, Fangyi Yao, Xin-Lu Wang, Zihao Wang, Bo Huang, Jing Liu, Xiaozhong Wang, Lei Zhang Frontiers in Immunology.2025;[Epub] CrossRef
Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova GASTROENTEROLOGY.2025; 59(3): 206. CrossRef
Repurposing HIV-Protease Inhibitor Precursors as Anticancer Agents: The Synthetic Molecule RDD-142 Delays Cell Cycle Progression and Induces Autophagy in HepG2 Cells with Enhanced Efficacy via Liposomal Formulation Fabiana Crispo, Antonio Vassallo, Immacolata Faraone, Alessandro Santarsiere, Lucia Chiummiento, Mara Martinelli, Nicoletta Cascelli, Xavier Fernàndez-Busquets, Rocchina Miglionico, Ilaria Nigro, Carla Caddeo, Maria Francesca Armentano International Journal of Molecular Sciences.2025; 26(21): 10305. CrossRef
The multidimensional role of SLC16A4 in hepatocellular carcinoma in silico analysis: prognostic significance, metabolic pathways, and immune microenvironment regulation Lili Jiang, Yi Shen, Zhengyang Feng, Yong Wang, Yaqun Zhu, Yuntian Shen, Qiliang Peng European Journal of Medical Research.2025;[Epub] CrossRef
MRI-based Habitat Imaging Enhances the Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Xiaogang Li, Anbin Hu Academic Radiology.2025;[Epub] CrossRef
The potential of soluble programmed cell death-ligand 1 and soluble programmed cell death 1 as diagnostic and prognostic biomarkers for hepatocellular carcinoma: a meta-analysis Jie Li, Xiangyang He, Tingting Gao, Qingjun Zhang, Xu Han Irish Journal of Medical Science (1971 -).2025;[Epub] CrossRef
Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma Zizhong Yang, Lupeng Qiu, Guhe Jia, Zhuoya Sun, Yixin Gong, Yin Chen, Yu Wang, Lai Song, Xiao Zhao, Shunchang Jiao BMC Cancer.2025;[Epub] CrossRef
Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments Yaru Shi, Yanan Bai, Jianglan Wu, Yunfeng Yu, Xinyu Yang, Haobo Yang, Weixiong Jian, Jun Qing Frontiers in Immunology.2025;[Epub] CrossRef
Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review Jiaxuan Wu, Xiaolong Tang, Qian Zheng, Xinhang Gu, Li Ma, Jinghong Xian, Hui Mao, Jiadi Gan, Guiyi Ji Frontiers in Oncology.2025;[Epub] CrossRef
miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma Mingxuan Lei, Jiayin Xu, Xiaoying Hu, Lin Feng, Baoping Luo BIOCELL.2025; 0: 1. CrossRef
Targeting endoplasmic reticulum stress-induced CLGN resensitizes hepatocellular carcinoma to apoptosis: paeonol synergistically enhances efficacy by dual inhibition of CLGN and NF-κB Sitong Yan, Anqi Wang, Xiang Chen, Weijia Jiang, Xiao Du, Yuhan Huang, Xiangyu Zu, Yue Zhu, Jiatao Liu, Lulu Fan, Lingling Zhang, Guoping Sun Frontiers in Oncology.2025;[Epub] CrossRef
Lactylation in Cancer: Unlocking the Key to Drug Resistance and Therapeutic Breakthroughs Xiangnan Feng, Dayong Li, Pingyu Wang, Xinyu Li, Guangyao Li Oncology Research.2025; 33(11): 3327. CrossRef
Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart International Journal of Molecular Sciences.2025; 26(23): 11547. CrossRef
Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer Weihao Kong, Long Teng, Kangjie Zhang, Yajun Zou, Xingyu Wang, Jianlin Zhang Biochemistry and Biophysics Reports.2025; 44: 102358. CrossRef
Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma Feng Yang, Shoufeng Chang, Ruxia Li, Jing Wei, Hua Zhang, Qiqi Wang, Zhenjun Li, Yamei Dang Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Early screening for liver cancer must be performed Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang World Journal of Hepatology.2025;[Epub] CrossRef
–A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative Yan An, Xiangyang Shi, Wentao Huang, Mingyi Shang, Guang-Zhi Jin Journal of Translational Medicine.2025;[Epub] CrossRef
Background/Aims Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is often asymptomatic and can go undiagnosed for years, leading to underuse of HCC surveillance in clinical practice. We characterized the frequency and associated factors of unrecognized cirrhosis in a national sample of patients with HCC from the United States.
Methods HCC patients aged 68 years and older, diagnosed during 2011 to 2015 were included from the SEERMedicare Linked Database. If cirrhosis was diagnosed within 6 months immediately preceding HCC diagnosis or after HCC diagnosis, cases were categorized as unrecognized cirrhosis. Factors associated with unrecognized cirrhosis were identified using logistic regression analyses. Factors associated with overall survival were evaluated using Cox regression analyses.
Results Among 5,098 HCC patients, 74.8% patients had cirrhosis. Among those with cirrhosis, 57.4% had unrecognized cirrhosis, with the highest proportion (76.3%) among those with NAFLD-related HCC. Male sex (aOR: 2.12, 95% CI: 1.83–2.46), non-Hispanic Black race (aOR: 1.93, 95% CI: 1.45–2.57), and NAFLD etiology (aOR: 4.46, 95% CI: 3.68–5.41) were associated with having unrecognized cirrhosis. Among NAFLD-related HCC patients, male sex (aOR: 2.32, 95% CI: 1.71–3.14) was associated with unrecognized cirrhosis. Unrecognized cirrhosis was independently associated with worse overall survival (aHR: 1.17, 95% CI: 1.08–1.27) compared to recognized cirrhosis.
Conclusions Unrecognized cirrhosis is common in NAFLD-related HCC, particularly among male and Black patients, highlighting these groups as important intervention targets to improve HCC surveillance uptake and outcomes.
Citations
Citations to this article as recorded by
Access to Evaluation for Liver Transplantation in the Veterans Health Administration Vera Yakovchenko, Michael F. Chang, Ruben Hernaez, Joseph A. Awad, Jennifer Anwar, Anna Nobbe, Heather McCurdy, Pratima Sharma, Patrick Spoutz, Manimegalai Murugavel, Mark A. Wilson, Jason A. Dominitz, Heather M. Patton, Megan A. Adams, Timothy R. Morgan, Digestive Diseases and Sciences.2025; 70(2): 552. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation Federico Carbone, Jean‐Pierre Després, John P. A. Ioannidis, Ian J. Neeland, Gabriella Garruti, Luca Busetto, Luca Liberale, Stefano Ministrini, Gemma Vilahur, Thomas H. Schindler, Maria Paula Macedo, Agostino Di Ciaula, Marcin Krawczyk, Andreas Geier, Gy European Journal of Clinical Investigation.2025;[Epub] CrossRef
Exploring the factors affecting the occurrence of postoperative MVI and the prognosis of hepatocellular carcinoma patients treated with hepatectomy: A multicenter retrospective study Jilin Yang, Junlin Qian, Zhao Wu, Wenjian Zhang, Zexin Yin, Wei Shen, Kun He, Yongzhu He, Liping Liu Cancer Medicine.2024;[Epub] CrossRef
Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu Medicine.2023; 102(32): e34637. CrossRef
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.
Citations
Citations to this article as recorded by
Long-Term Survival and Recurrence in HCC vs. Non-HCC Liver Transplant Recipients: A Two-Decade Longitudinal Analysis Mahmoudreza Moein, Bridgette Nixon, Michael Leyderman, Ali Bassir, Brenden Maloney, Abolfazl Jamshidi, Matin Moallem Shahri, Amin Bahreini, Alireza Golkarieh, Reza Saidi Journal of Clinical and Experimental Hepatology.2025; 15(3): 102489. CrossRef
Editorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure Tung‐Hung Su, Wei‐Chih Liao Alimentary Pharmacology & Therapeutics.2025; 61(3): 583. CrossRef
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials Tripti Khare, Karina Liu, Lindiwe Oslee Chilambe, Sharad Khare International Journal of Molecular Sciences.2025; 26(1): 306. CrossRef
A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease Byeong Geun Song, GoEun Park, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Journal of Gastroenterology and Hepatology.2025; 40(4): 979. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study Chang Hun Lee, Min Gu Kang, Shinyoung Oh, In Sun Goak, Chen Shen, Ha Ram Oh, Young Ran Park, Jong Seung Kim, Ji Hyun Park Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102612. CrossRef
High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao Clinical and Molecular Hepatology.2025; 31(3): 796. CrossRef
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid Cureus.2025;[Epub] CrossRef
Association Between Dietary Inflammatory Index and NAFLD: A Cross‐Sectional Study of the National Health and Nutrition Examination Survey Yuan He, Yuhang Yang, Pengfei Cheng, Wei Zhang, Jinghan Jia, Dawei Ye, Jinxi Wang, Jasbir Arora (RSS) Mediators of Inflammation.2025;[Epub] CrossRef
Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control Xianwen Chen, Junnan Shi, Yan Xue, Yunfeng Lai, Menghuan Song, Carolina Oi Lam Ung, Hao Hu Global Health Research and Policy.2025;[Epub] CrossRef
A CART-based prognostic model for risk stratification of postoperative early recurrence in hepatocellular carcinoma with microvascular invasion Jie Zeng, Ri-Jin Lu, Zheng Tao, Can Zeng, Kai-Xiang Mo, Weijie Cen, Yan Lin, Rong Liang, Le-Qun Li, Guo-Bin Wu, Jia-Zhou Ye, Rong-Yun Mai Frontiers in Oncology.2025;[Epub] CrossRef
A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma Shi-Chuan Tang, Kai-Ling Zhang, Kong-Ying Lin, Yi-Dan Tang, Jun Fu, Wei-Ping Zhou, Jian-Xi Zhang, Jie Kong, Xiao-Lu He, Zheng-Hong Sun, Cong Luo, Hong-Zhi Liu, Yong-Ping Lai, Yong-Yi Zeng Hepatology International.2024; 18(2): 623. CrossRef
A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis Gi‐Ae Kim, Yewan Park, Shin Ju Oh, Jooyi Jung, Seungbong Han, Hye‐Sook Chang, Sung Won Park, Tae Hyup Kim, Hye Won Park, Jaewon Choe, Jaeil Kim, Han Chu Lee Liver International.2024; 44(3): 738. CrossRef
Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease Wei Ouyang, Ming-Da Wang, Ming-Cheng Guan, Yong-Kang Diao, Li-Yang Sun, Nan-Ya Wang, Feng Shen, Hong Zhu, Tian Yang iLIVER.2024; 3(2): 100098. CrossRef
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions Yang Ma, Jinguo Wang, Wenping Xiao, Xiaoming Fan Frontiers in Medicine.2024;[Epub] CrossRef
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim Clinical and Molecular Hepatology.2024; 30(3): 360. CrossRef
Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes Wonkyung Han, Kyungdo Han, Seong Gyu Hwang, Sang Hoon Ahn, Mi Na Kim JHEP Reports.2024; 6(10): 101166. CrossRef
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options Yuming Shi, Erfan Taherifard, Ali Saeed, Anwaar Saeed Current Issues in Molecular Biology.2024; 46(6): 5965. CrossRef
Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets Yazan Abboud, Vraj P. Shah, Michael Bebawy, Ahmed Al-Khazraji, Kaveh Hajifathalian, Paul J. Gaglio Journal of Clinical Medicine.2024; 13(17): 5256. CrossRef
Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations D.K. Sabir, J.A. Bin Jumah, I. Ancy SAR and QSAR in Environmental Research.2024; 35(11): 1045. CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The latest global burden of liver cancer: A past and present threat Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 355. CrossRef
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas Diagnostics.2023; 13(16): 2631. CrossRef
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available if detected at an early stage. However, two thirds of patients with HCC are diagnosed at a late stage and not eligible for cure. Therefore several liver professional societies recommend HCC surveillance using abdominal ultrasound with or without alpha fetoprotein in at-risk populations, including patients with cirrhosis and subsets of those with chronic hepatitis B. Available data suggest HCC surveillance can significantly improve early tumor detection, curative treatment eligibility, and overall survival. However, the potential benefits of HCC surveillance must be considered in light a shifting HCC demographic from a viral-mediated cancer to an increasing proportion of patients having non-alcoholic steatohepatitis, which has been shown to limit ultrasound sensitivity and may mitigate observed benefits. Further, benefits of HCC surveillance must be weighed against potential physical, financial and psychological harms. Continued data for both benefits and harms of HCC surveillance in contemporary populations are necessary. In the interim, providers should continue to strive for high quality HCC surveillance in at-risk patients.
Citations
Citations to this article as recorded by
Composite bioreactor for synergistic Modulation of tumor microenvironment and endogenous Regulation of ROS generation to enhance chemodynamic therapy for lung cancer Longhao Lv, Yong Liu, Chengsong Cao, Yong Li, Zhengshuai Tang, Jinliang Liu Journal of Colloid and Interface Science.2025; 683: 918. CrossRef
Activatable fluorescent probes for imaging and diagnosis of hepatocellular carcinoma Xiaoxiao Men, Fanghong Liu, Mingyue Gong, Xuchao Wang, Ling Wang, Xiaoju Men, Haobin Chen, Zhuxin Dong Journal of Innovative Optical Health Sciences.2025;[Epub] CrossRef
Impact of Add‐On Hepatobiliary Abbreviated Magnetic Resonance Imaging on Ultrasound Hepatoma Surveillance for Liver Cirrhosis‐ a Randomized Study Jing‐Houng Wang, Hsin‐You Ou, Yi‐Hao Yen, Chao‐Hung Hung, Sheng‐Nan Lu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Three-year of hepatocellular carcinoma surveillance in patients with cirrhosis diagnosed between 2009 and 2013: a cohort study based on the French National Health Data System (SNDS) claims data Pascal Caillet, Fréderic Balusson, Nathalie Ganne-Carié, Emmanuel Oger, Charlotte Costentin, Olivier Ganry Frontiers in Oncology.2025;[Epub] CrossRef
Deep Learning-Based Prediction of Post-treatment Survival in Hepatocellular Carcinoma Patients Using Pre-treatment CT Images and Clinical Data Kyung Hwa Lee, Jungwook Lee, Gwang Hyeon Choi, Jihye Yun, Jiseon Kang, Jonggi Choi, Kang Mo Kim, Namkug Kim Journal of Imaging Informatics in Medicine.2024; 38(2): 1212. CrossRef
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom Osvaldo Ulises Garay, Louisa Elena Ambühl, Thomas G. Bird, Eleanor Barnes, William L. Irving, Ryan Walkley, Ian A. Rowe Value in Health.2024; 27(12): 1698. CrossRef
Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma Minami Yamauchi, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Mio Tsuruoka, Jun Inoue, Atsushi Masamune, Nariyasu Mano Metabolites.2024; 14(9): 513. CrossRef
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? Neehar D. Parikh, Nabihah Tayob, Amit G. Singal Journal of Hepatology.2023; 78(1): 207. CrossRef
KRT17 serves as an oncogene biomarker of poor survival in patients with hepatocellular carcinoma Jing-Lin Wang, Lu Zhang, Chen-Zhuo Xu, Xue-Qian Qin, Shu-Jun Liu, Bao-Jie Wen, Hao-Zhen Ren Biomedical Technology.2023; 3: 18. CrossRef
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chan Clinical and Molecular Hepatology.2023; 29(2): 277. CrossRef
Should we undertake surveillance for HCC in patients with MAFLD? Blanca Norero, Jean-François Dufour Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub] CrossRef
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2023; 29(2): 453. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi, Hepatology.2023; 77(5): 1746. CrossRef
Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis Jaideep Behari, Amir Gougol, Renwei Wang, Hung N. Luu, Pedram Paragomi, Yi-Chuan Yu, Michele Molinari, Kapil Chopra, Shahid M. Malik, David Geller, Jian-Min Yuan Hepatology Communications.2023;[Epub] CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
Risk factors and prevention of liver cancer: A bibliometric and visual analysis Min Yang, Huiqin Zhang, Jieqiu Zhang, Xiaopeng Yao Medicine.2023; 102(47): e35740. CrossRef
Comparative long‐term outcomes of laparoscopic hepatectomy and radiofrequency ablation for hepatocellular carcinoma located in the anterolateral segments of the liver Sungho Kim, Chang Jin Yoon, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Moonhwan Kim, Boram Lee, Soyeon Ahn Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(3): 349. CrossRef
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim American Journal of Gastroenterology.2022; 117(2): 288. CrossRef
Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Digestive Diseases and Sciences.2022; 67(7): 3412. CrossRef
Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Seong Gyu Hwang International Journal of Cancer.2022; 150(10): 1587. CrossRef
Achievement of textbook outcomes and comparisons with benchmark values after laparoscopic left lateral sectionectomy Mizelle D’Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim Updates in Surgery.2022; 74(4): 1299. CrossRef
Risk Prediction Model Based on Magnetic Resonance Elastography-Assessed Liver Stiffness for Predicting Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma Hyo Jung Cho, Young Hwan Ahn, Min Suh Sim, Jung Woo Eun, Soon Sun Kim, Bong Wan Kim, Jimi Huh, Jei Hee Lee, Jai Keun Kim, Buil Lee, Jae Youn Cheong, Bohyun Kim Gut and Liver.2022; 16(2): 277. CrossRef
Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari PLOS ONE.2022; 17(3): e0265668. CrossRef
Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study Ha Il Kim, Jihyun An, Ji Yoon Kim, Hyun Phil Shin, Seo Young Park, Gi-Won Song, Han Chu Lee, Ju Hyun Shim Liver Cancer.2022; 11(2): 141. CrossRef
Deubiquitylating Enzyme OTUB2 Promotes the Progress of Liver Cancer Cells by Stabilizing TRIM54 An Wang, Xiaofeng Chen, Dongen Li, Liang Yang, Jianshuai Jiang International Journal of Pharmacology.2022; 18(4): 633. CrossRef
Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify Philip J. Johnson, Hamish Innes, David M. Hughes, Anton Kalyuzhnyy, Takashi Kumada, Hidenori Toyoda British Journal of Cancer.2022; 127(7): 1263. CrossRef
Applications of molecular barcode sequencing for the detection of low‐frequency variants in circulating tumour DNA from hepatocellular carcinoma Hye Won Lee, Esl Kim, Kyung Joo Cho, Hye Jung Park, Jieun Seo, Hyeonah Lee, Eunha Baek, Jong Rak Choi, Kwang‐Hyub Han, Seung‐Tae Lee, Jun Yong Park Liver International.2022; 42(10): 2317. CrossRef
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease Won Sohn, Danbee Kang, Minwoong Kang, Eliseo Guallar, Juhee Cho, Yong-Han Paik Clinical and Molecular Hepatology.2022; 28(4): 851. CrossRef
Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim Journal of Liver Cancer.2022; 22(2): 125. CrossRef
Factors associated with nonadherence to surveillance for hepatocellular carcinoma among patients with hepatic C virus cirrhosis, 2000–2015 Shen-Shong Chang, Hsiao-Yun Hu, Feng-Shiang Cheng, Yu-Chin Chen, Yung-Feng Yen, Nicole Huang Medicine.2022; 101(47): e31907. CrossRef
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim Journal of Viral Hepatitis.2021; 28(1): 95. CrossRef
Improved Outcomes of Laparoscopic Liver Resection for Hepatocellular Carcinoma Located in Posterosuperior Segments of the Liver Yujin Kwon, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonwhan Kim World Journal of Surgery.2021; 45(4): 1178. CrossRef
Metabolic disease as a risk of hepatocellular carcinoma Naoshi Nishida Clinical and Molecular Hepatology.2021; 27(1): 87. CrossRef
Addition of liver stiffness enhances the predictive accuracy of the PAGE‐B model for hepatitis B‐related hepatocellular carcinoma Hye Yeon Chon, Han Ah Lee, Sang Jun Suh, Jung Il Lee, Byung Seok Kim, In Hee Kim, Chang Hyeong Lee, Byoung Kuk Jang, Hyun Woong Lee, Jae Seok Hwang, Chang Hun Lee, Jin‐Woo Lee, Jung Hwan Yu, Yeon Seok Seo, Hyung Joon Yim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2021; 53(8): 919. CrossRef
Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy Fatih Güzelbulut, Pınar Gökçen, Güray Can, Gupse Adalı, Ayça Gökçen Değirmenci Saltürk, Özgür Bahadır, Kamil Özdil, Hamdi Levent Doğanay Journal of Viral Hepatitis.2021; 28(5): 826. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B Hye Yeon Chon, Yeon Seok Seo, Jung il Lee, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, In Hee Kim, Jin-Woo Lee, Young Eun Chon, Moon Young Kim, Soung Won Jeong, Han Ah Lee, Sun Young Yim, Soon Ho Um, Hyun Woong Lee, Kwan Sik Lee, Jeong Eu European Journal of Gastroenterology & Hepatology.2021; 33(6): 885. CrossRef
External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China Tao Lou, Bin Li, Pian Xiong, Caiting Jin, Yagang Chen Journal of Viral Hepatitis.2021; 28(10): 1373. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy Weihe Yao, Chenyu Liu, Ning Wang, Hengjun Zhou, Hailiang Chen, Weihong Qiao Journal of Colloid and Interface Science.2021; 603: 783. CrossRef
Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma Han Ah Lee, Young-Sun Lee, Beom Kyung Kim, Young Kul Jung, Seung Up Kim, Jun Yong Park, Ji Hoon Kim, Hyunggin An, Do Young Kim, Hyung Joon Yim, Sang Hoon Ahn, Jong Eun Yeon, Kwan Soo Byun, Kwang-Hyub Han, Soon Ho Um, Yeon Seok Seo Gut and Liver.2021; 15(3): 420. CrossRef
Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma Fuan Wang, Chuan Xu, Guiling Li, Penghua Lv, Jianping Gu Experimental Cell Research.2021; 409(2): 112910. CrossRef
Factors Associated with Poor Self-Rated Health in Cancer Patients Hyo Rim Ju, Ye Rim Jeon, Seo Young Kang, Jung Ah Lee, Young Sik Kim Korean Journal of Family Practice.2021; 11(5): 385. CrossRef
Expression and clinical significance of BDH1 in liver cancer Zhicheng Liu, Yanqing Li, Ying Liu, Dingquan Yang, Yan Jiao, Yunpeng Liu Medicine.2021; 100(48): e28013. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea” Beom Kyung Kim Journal of Hepatology.2020; 72(1): 198. CrossRef
Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer Dingquan Yang, Yan Jiao, Yanqing Li, Xuedong Fang PeerJ.2020; 8: e8252. CrossRef
Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(9): 2527. CrossRef
Improved outcomes of major laparoscopic liver resection for hepatocellular carcinoma Hyo Jun Kim, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Junyub Kim Surgical Oncology.2020; 35: 470. CrossRef
New advances in the diagnosis and management of hepatocellular carcinoma Ju Dong Yang, Julie K Heimbach BMJ.2020; : m3544. CrossRef
Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma Yuri Cho, Min Ji Park, Koeun Kim, Sun Woong Kim, Wonjin Kim, Sooyeon Oh, Joo Ho Lee World Journal of Gastroenterology.2020; 26(42): 6599. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data Jun Sik Yoon, Byeong Geun Song, Jeong-Hoon Lee, Hyo Young Lee, Sun Woong Kim, Young Chang, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon BMC Cancer.2019;[Epub] CrossRef
First
Prev
